SubHero Banner
Text

September 2024

Core topics in this month’s edition include:

  • Ocrevus Zunovo™ (ocrelizumab/hyaluronidase-ocsq)– new drug approval
  • Otulfi™ (ustekinumab-aauz) - new biosimilar
  • Tagrisso® (osimertinib) - new indication

Download PDF

Text